Who are the real high-risk patients with pathological T2N0M0 non-small-cell lung cancer that can benefit from adjuvant chemotherapy?

por Hou, X., Yang, M.-Z., Li, J.-B., Tan, Z.-H., Long, H., Fu, J.-H., Zhang, L.-J., Lin, P., Yang, H.-X.
Publicado 2022